Search Medical Condition
Please enter condition
Please choose location
 

Venissieux, France Clinical Trials

A listing of Venissieux, France clinical trials actively recruiting patients volunteers.

RESULTS

Found (725) clinical trials

Prevalence of Pancreatic Anomalies of Patients With a 1st Degree Familial History of Pancreatic Adenocarcinoma

Pancreatic adenocarcinoma is the 4th leading cause of cancer in the USA. Its incidence is increasing both in France and in Europe, whereas all the other cancers are decreasing in Europe. Moreover, its seriousness is still high, with a mortality rate higher than the average incidence. The aim of PAPAFA ...

Phase N/A

0.0 miles

Learn More »

Evaluation of the DIABEO System in Poorly Controlled DM1 or DM2 Patients Treated With a Basal-bolus Insulin Regimen

The aim of the TELESAGE study is to demonstrate the superiority of follow up with the DIABEO system (software alone) versus usual follow up in terms of improvement in HbA1c after 1 year in DM1 or DM2 patients treated with a basal-bolus insulin regimen. the superiority of follow up with ...

Phase N/A

0.33 miles

Learn More »

A Long-Term Registry of Humira (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)

This is a registry study to evaluate the long-term safety and effectiveness of adalimumab in patients with moderately to severely active UC who are treated as recommended in the product label.

Phase N/A

0.33 miles

Learn More »

Investigation of Efficacy and Safety of Three Dose Levels of Subcutaneous Semaglutide Once Daily Versus Placebo in Subjects With Non-alcoholic Steatohepatitis.

Investigation of efficacy and safety of three dose levels of subcutaneous semaglutide once daily versus placebo in subjects with non-alcoholic steatohepatitis

Phase

0.33 miles

Learn More »

Research Study Comparing a New Medicine Semaglutide to Liraglutide in People With Type 2 Diabetes

This study is conducted in Europe. The aim of the study is to compare the effect of semaglutide subcutaneous (s.c., under the skin) 1.0 mg once-weekly to liraglutide s.c.1.2 mg once-daily on blood sugar levels after 30 weeks of treatment in people with type 2 diabetes. The study will last ...

Phase

0.33 miles

Learn More »

Impact of a Transitional Care Program on 30-Day Hospital Readmissions for Elderly Patients Discharged From a Short Stay Geriatric Ward

The study is a stepped wedge randomized cluster study. Intervention: The transition care program, involving a dedicated advanced practice nurse, will include: 1) during the patient's stay in hospital: an individualized needs-based comprehensive discharge plan and a transitional care record ; the notification of the primary care physician about inpatient ...

Phase N/A

0.33 miles

Learn More »

Validation of Algorithms for Basal Insulin Rate Reductions in Type 1 Diabetic Patients Practising Physical Activity in Real Life Conditions

There is no specific recommendations on the adjustments of the insulin treatment in the event of physical activity (PA) in T1D patients treated on insulin pump therapy. Patients often prefer additional carbohydrates intake rather than the reduction of their insulin doses because of the lack of specific algorithms. The DIABRASPORT ...

Phase N/A

0.33 miles

Learn More »

Post-Marketing Use Of Inflectra (Infliximab) For Standard Of Care Treatment Of Inflammatory Bowel Disease

The study will be conducted according to good clinical practice (GCP) guidelines and data source will be validated. The source data will consist of the hospital medical records and monitoring will be organized on a regular basis. Data for the study will be entered into an web based electronic data ...

Phase N/A

0.86 miles

Learn More »

Assessing Effectiveness of Adalimumab for Treating Ulcerative Colitis in Real Life Conditions

This study assesses the longterm effectiveness of adalimumab in subjects starting a treatment for ulcerative colitis in real life conditions, namely to describe the time to loss of clinical benefit in a time to event approach.

Phase N/A

0.86 miles

Learn More »

Circulating Tumor DNA and Follow-up of BRCA1 Mutation Carriers (CirCa 01)

BRCA1 carriers who are at high risk of developing either a relapse and/or a new cancer growth will be included. These patients will be followed up during 30 months (2,5 years) with mutated TP53 mutation detection or during 42 months (3,5 years) with mutated TP53 mutation detection and circulating tumor ...

Phase N/A

1.39 miles

Learn More »